Passariello N, Giugliano D, Sgambato S, Torella R, D'Onofrio F
J Clin Endocrinol Metab. 1981 Aug;53(2):318-23. doi: 10.1210/jcem-53-2-318.
The effect of calcitonin on oral glucose tolerance and on insulin, C-peptide, glucagon, and GH secretion has been investigated in man. Eight subjects with normal glucose tolerance and eight with impaired glucose tolerance (IGT) were studied. Each subject received two oral glucose tolerance tests (100 g) in random order, one under basal conditions and the other during the simultaneous in administration of salmon calcitonin (100 Medical Research Council Units). In all subjects, calcitonin exaggerated the rise in plasma glucose after oral sugar. The integrated areas under the plasma glucose curves were 4,400 +/- 840 mg/dl.min (normals) and 8,708 +/- 1,840 mg/dl.min (IGT) without calcitonin, and 8,208 +/- 1,700 mg/dl. min (normals) and 19,500 +/- 3,500 mg/dl. min (IGT) with calcitonin (P less than 0.01). Plasma insulin and C-peptide responses to glucose were significantly reduced (P less than 0.01) by calcitonin at all times after the start of the test in both normal and IGT groups. The inhibitory action of oral glucose on glucagon secretion was partially prevented by calcitonin (P less than 0.01). Moreover, calcitonin completely blunted the GH rebound occurring at the end of the test. These findings demonstrate that calcitonin impairs glucose tolerance in man by both inhibiting glucose-induced insulin secretion (primary effect) and reducing glucose-mediated glucagon suppression (accessory effect). These effects of calcitonin could be explained by a decrease in the cytosolic Ca2+ concentration in both alpha- and beta-cells.
已在人体中研究了降钙素对口服葡萄糖耐量以及胰岛素、C肽、胰高血糖素和生长激素分泌的影响。研究了8名葡萄糖耐量正常的受试者和8名葡萄糖耐量受损（IGT）的受试者。每位受试者随机接受两次口服葡萄糖耐量试验（100克），一次在基础条件下进行，另一次在同时给予鲑鱼降钙素（100个医学研究委员会单位）期间进行。在所有受试者中，降钙素均使口服糖后血浆葡萄糖的升高加剧。在未使用降钙素时，血浆葡萄糖曲线下的积分面积在正常受试者中为4400±840mg/dl·min，在IGT受试者中为8708±1840mg/dl·min；使用降钙素时，正常受试者中为8208±1700mg/dl·min，IGT受试者中为19500±3500mg/dl·min（P<0.01）。在正常组和IGT组中，试验开始后的所有时间，降钙素均使血浆胰岛素和C肽对葡萄糖的反应显著降低（P<0.01）。降钙素部分阻止了口服葡萄糖对胰高血糖素分泌的抑制作用（P<0.01）。此外，降钙素完全消除了试验结束时出现的生长激素反跳。这些发现表明，降钙素通过抑制葡萄糖诱导的胰岛素分泌（主要作用）和减少葡萄糖介导的胰高血糖素抑制（辅助作用）损害人体的葡萄糖耐量。降钙素的这些作用可以通过α细胞和β细胞中胞质Ca2+浓度的降低来解释。
